The subscription period in Stayble Therapeutics’ rights issue begins today
Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The general public is also given the opportunity to subscribe for shares in the Rights Issue. The subscription period lasts until 17 February 2021 and a fully subscribed Rights Issue will provide the Company with approximately SEK 41.5 million before issue costs. Stayble has received subscription commitments and guarantee (top-down) commitments in advance, corresponding to a total of